Shares in pharmaceutical giant Novartis (NVS) were flat in pre-market trading today despite reporting an 11% surge in Q2 sales.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The group said demand for medicines such as breast cancer drug Kisqali and cardiovascular drug Entresto had been strong. It also raised its guidance for core operating income in 2025.